Otsuka Pakistan Limited (PSX: OTSU) has resumed full production at its Hub plant effective January 5, 2026, following the successful completion of its planned annual maintenance shutdown, the company disclosed today. This positive development lifted investor confidence, with OTSU shares jumping to Rs355.50, up Rs14.63 (4.29%) in early trading on the Pakistan Stock Exchange.
Otsuka Pakistan is a leading pharmaceutical company in Pakistan, incorporated in 1988 and operating as an indirect subsidiary of Japan’s Otsuka Pharmaceutical Co. Ltd. The company manufactures, markets, and distributes intravenous infusion solutions, clinical nutrition products, therapeutic drugs and medical devices in Pakistan and neighboring markets. Its product range includes electrolyte and carbohydrate infusions, clinical nutrition formulas, and medicines such as Pletaal and Mucosta.
The annual shutdown for preventive maintenance is a routine industry practice designed to ensure plant safety, comply with quality standards and sustain uninterrupted future production. The last scheduled maintenance earlier in December 2025 paused operations briefly ahead of the restart today.
Following the resumption of operations, the market reacted positively. A company spokesperson noted, “Production has resumed as scheduled, ensuring continuity in supply and reinforcing our commitment to quality healthcare products.” This reassurance appears to have influenced the stock’s upward movement and bolstered stakeholder confidence.
Otsuka Pakistan’s consistent operations are crucial for the healthcare supply chain, particularly for intravenous and clinical nutrition products widely used in hospitals and medical facilities across the region.